TCI B6055 (SB 225002, CAS 182498-32-4) is a potent and selective non-peptide antagonist of the CXCR2 interleukin-8 (IL-8) receptor, widely utilized in cancer research and cell biology studies. This compound is commonly applied in investigations of tumor metastasis, angiogenesis, and inflammatory signaling pathways associated with oncogenesis. Available in 10 mg and 50 mg packaging options under the TCI brand, it is a reliable reagent for laboratories conducting advanced biomedical and pharmacological research.
—
| Brand | — |
|---|---|
| CAS number | — |
| Molecular formula | — |
| Purity | — |
| Category | — |
| Pack sizes | — |
| Physical form | — |
| Storage | — |
—
—






